VIENNA — The interleukin 1 receptor antagonist (IL-1RA) canakinumab provided control of systemic juvenile idiopathic arthritis (sJIA) without the use of glucocorticoids for up to a year in most study ...

First it was heart disease, now it’s non-small cell lung cancer (NSCLC). Novartis can’t seem to make its canakinumab injection work outside immunology, where the drug’s currently sold as Ilaris. The ...

The European Commission has approved canakinumab (Ilaris, Novartis) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded ...

There are currently no medications that can slow down the common form of arthritis that strikes aging knees and hips. But a new study suggests a powerful, and expensive, anti-inflammatory drug could ...

ORLANDO, Fla.—When Novartis released results from a 10,000-patient trial examining canakinumab—already approved as rare disease med Ilaris—last year at the European Society of Cardiology, analysts ...

Please provide your email address to receive an email when new articles are posted on . In two clinical trials, the inhibition of interleukin-1 beta combined with either canakinumab or anakinra did ...

Please provide your email address to receive an email when new articles are posted on . “The exciting finding here is that we are opening up a new field of understanding in the causes of ...

An exploratory analysis of data from the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) randomized double-blind, placebo-controlled trial found that patients receiving interleukin-1β ...